RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Pre-progression health state utility values from the TALAPRO-2 clinical trial in patients with metastatic castration-resistant prostate cancer unselected for DDR mutations
Niyazov, A., Simou, E., Kirker, M., Houghton, K., Le moine, J. G., Chang, J., Yarr, S., Barnett, C., & Mladsi, D. D. (2023). Pre-progression health state utility values from the TALAPRO-2 clinical trial in patients with metastatic castration-resistant prostate cancer unselected for DDR mutations. Value in Health, 26(12), S149. https://doi.org/10.1016/j.jval.2023.09.772